News
Report: The role of technology in advancing endometriosis care

This report has been created from a webinar featuring Paulina Cecula, Co-founder, Dama Health, Lara Zibners, Co-founder, Calla Lily Clinical Care, Tara Harding, Clinician & Owner, Simply You Clinic, and Bianca Schor, Researcher, University of Cambridge, Amsterdam University Medical Center.
The discussion looked at the systemic challenges and necessary advancements in the diagnosis and treatment of endometriosis with a focus on provider education, patient empowerment, and clinical technology integration.
- Endometriosis affects roughly 10 per cent of reproductive age women and girls. That is around 190 million people globally.
- There is no known cure for endometriosis and so treatment is aimed at controlling symptoms.
- Current standard treatments for endometriosis are mainly hormonal contraceptives and surgery which are outdated, with 30–40 per cent of patients not responding well.
- Early diagnosis is a key factor in the treatment of endometriosis but is limited in many ways.
Challenges in advancing innovation and research in endometriosis
Funding:
- Funding is the core obstacle, especially for early-stage, data-intensive work.
- Grants often favor entities that already have data, creating a catch-22 for startups trying to build datasets from the ground up.
Data:
Lack of readily-available data
- Women’s health, especially endometriosis, lacks foundational data compared to fields like oncology, where partnerships with electronic medical records (EMR) and existing data are common.
- Startups must collect and build datasets from scratch, creating a high barrier to entry.
Quality and accessibility of data
- Existing EMR data often lacks the quality needed to identify or track endometriosis cases.
- The goal is multi-modal datasets (genetics, microbiome, symptom patterns), but this is currently being done only at small scales.
Education:
Outdated education and research barriers
- Persisting myths like retrograde menstruation being the cause of endometriosis continue to affect medical education.
- Funding often goes to legacy researchers, even if their data and methodology are outdated.
- Empowered patients are a huge asset, but they must be supported by informed, open-minded, and up-to-date clinicians.
Expertise gap
- Many patients are misdiagnosed or delayed in care due to providers falsely claiming expertise.
- Standardised credentials (e.g., ACOG-assessed qualifications) are urgently needed to help patients access true specialists.
- There’s a need for clinical expertise to interpret medical data, especially for those from non-medical backgrounds (e.g., computer scientists).
- Effective research requires interdisciplinary collaboration.
Need for collaboration
- Recent progress has come from private companies joining forces, e.g., the 700,000-patient genetic study by
23andMe and Semantics. - Collaborative efforts are key to pooling data and expertise.
Patient-led advocacy & the risks of misinformation
- Patients are increasingly using technology to self-educate and self-advocate.
- There’s a double-edged sword: patients may fall victim to misinformation or unqualified influencers (e.g.,vaginal steaming).
- Providers must be equipped to interpret patient-driven data and respond with clinical expertise.
Diagnosis:
Early screening and intervention
- Childhood endometriosis remains vastly under-researched and poorly supported.
- Legal and structural barriers even prevent access to care in some countries.
- Screening should begin in adolescence and include school nurses, pediatricians, and underserved clinics.
- Tools should reflect the full-body nature of endometriosis, not just “painful periods.”
- A key challenge remains that there’s no current way to predict which treatments will work for which patients, leading to a long and painful trial-and-error process that can worsen disease progression.
Societal normalisation of menstrual pain
- Adolescents often feel too ashamed to speak about symptoms, leading to missed diagnoses.
- Cultural messaging continues to reinforce the idea that extreme period pain is “normal.”
Technology:
Systemic Inefficiencies
- There’s fragmentation and competition in the space, with limited data sharing.
- A lack of alignment between innovation, reimbursement, and regulatory approval leads to inertia in adoption.
Clinical workflow integration
- Tools must integrate into existing EMR systems and workflows to be adopted widely by clinicians.
- Patients presenting external test results often drive clinicians to stay current and adapt their care.
The future of endometriosis diagnosis and treatment
Although there are many challenges to overcome across all stakeholders involved in the care system, there is hope that we can improve the time it takes to diagnose endometriosis, and the treatments available through increasing personalisation and new and ongoing research.
New treatments are in development—including immunologic and antibody-based therapies—but rigorous clinical trials are needed before they can be implemented at scale and make a material difference to those with enbodmetriosis.
In the short term, personalising how current treatments are prescribed could bridge the gap.
For example, there are ongoing studies to identify hormone responders vs. non-responders which could assist in this.
Despite the pressing need for advancement, we must acknowledge that there is a danger to prioritising speed over scientific rigor given past examples of prematurely released medical solutions that proved unsafe or ineffective.
There is also a need to prevent reverse financial incentives where profit could overshadow patient well-being, particularly around unvalidated diagnostic tools.
Conclusion
It’s clear that we are long overdue for a systemic reset in how we diagnose and manage endometriosis.
With earlier intervention, better provider education, empowered patients, and technology that actually fits the healthcare system, change is not only possible—it’s essential.
This year, WHIS is taking place on 5-6 November, bringing together the entire women’s health eco-system to spotlight the opportunities and challenges within the industry. Our curated programme and audience of change makers accelerate innovation, increase access and bridge healthcare gaps.
If you would like to watch the full webinar on-demand, you can view it here.
Wellness
Study links small bowel microbiome differences to women’s health
Menopause
Cancer drug could tackle osteoporosis menopause weight gain

An experimental cancer drug reduced bone loss and body fat in mice modelling post-menopausal changes, early research suggests.
The compound, CADD522, appeared to strengthen bones and help the animals stay leaner after surgery designed to mimic hormonal changes seen after menopause.
The treatment remains at an early experimental stage and has so far only been tested in animals.
The study, led by the University of East Anglia, investigated CADD522, which was originally developed to block a protein involved in the growth and spread of several cancers.
Mice treated with the compound for eight weeks showed significant improvements in bone health. Scans found increased bone volume and better preservation of the honeycomb-like structures inside bones that are crucial for strength and resilience.
Blood tests suggested the treatment stimulated new bone growth without interfering with the body’s normal process of breaking down and rebuilding bone.
Dr Darrell Green, lead researcher from UEA’s Norwich Medical School, said: “Osteoporosis affects around one in three women over the age of 50, leaving sufferers vulnerable to painful fractures that can seriously impact quality of life.
“Current treatments exist, but many are plagued by side effects, safety concerns or inconvenient dosing schedules that make long-term use difficult.”
The researchers also found that mice receiving CADD522 weighed less than untreated mice despite eating the same amount of food.
They had less body fat and fewer fat deposits in their bone marrow, a process commonly seen after menopause and linked to declining bone health.
The team also examined brain tissue and found that the drug appeared to reverse several menopause-related changes in fatty acids.
Levels of omega-3 fats including DHA remained largely intact, while several other lipid abnormalities shifted back towards healthier patterns.
Green said: “We didn’t directly test for memory or thinking ability, but our work raises questions about whether this drug could one day help address wider menopause-related health problems.”
Safety experiments in mice, rats and dogs found that CADD522 could be taken orally and was well tolerated.
The compound also appeared to be metabolised more slowly in human tissue than in rodents, potentially improving its performance in people.
“This is still in the early stages and has so far only been tested in animals but we hope that the benefits will translate to humans to ultimately reduce fracture rates,” added Green.
The research was led by UEA in collaboration with the University of Maryland, the Scintillon Research Institute in San Diego and the University of Stirling.
Safety testing was funded by The Sir William Coxen Trust as part of the development of CADD522 as a childhood cancer treatment.
Fertility
Weight loss surgery improves menstrual health and PMOS symptoms, study finds

Weight loss surgery was linked to more regular periods and fewer polyendocrine metabolic ovarian syndrome (PMOS) symptoms in women aged 18 to 45 living with obesity in a recent study.
The researchers recommend that women undergoing the procedure have access to preconception care and reproductive counselling to support their reproductive health.
Researchers at the University of Surrey analysed data over 24 months from 84 women who underwent bariatric surgery and 18 women living with obesity who did not have surgery.
Of those who underwent surgery, 49 had gastric bypass procedures and 35 had gastric sleeve surgery.
Women who underwent metabolic bariatric surgery lost more than 30kg on average at 12 and 24 months after the procedure.
Among women with polycystic ovaries, the condition persisted in only 10 per cent after 24 months.
Women also reported a resolution of clinical hirsutism, or excess body hair, by 12 months.
Women who had previously experienced irregular periods reported more regular menstrual cycles after surgery.
Professor Martin Whyte, co-author of the study and professor of metabolic medicine at the University of Surrey, said: “A large proportion of those undergoing bariatric surgery are women of reproductive age, who may be planning a pregnancy in the coming years.
“So much remains unknown about the impact of this type of surgery on women who are planning to have children.
“This raises the question of when the ideal time after surgery is to conceive.”
Women have a higher prevalence of obesity than men, with 57 per cent of women in the UK classified as overweight and 27 per cent living with obesity, which can affect fertility and the health of an unborn baby.
The researchers said 17 women had healthy pregnancies following surgery.
Although this was not specifically examined in the study, no difference in birth weight was observed between babies conceived within or after the first year.
Dr Kathryn Hart, co-author of the study and associate professor in nutrition and dietetics at the University of Surrey, said: “What we have found is that bariatric surgery positively affects the reproductive health of women living with obesity and can improve the likelihood of them having a healthy pregnancy after surgery.
“Dysregulated hormone levels, irregular periods and conditions such as polycystic ovaries are affected by obesity.
“By reducing this, what we have seen is that it can lead to improvements without the need for medication.
“We would suggest that clinicians consider medical intervention for obesity to treat irregularities in the menstrual cycle and issues with fertility.”
Diagnosis2 weeks agoMajor UK study could be a ‘game-changer’ for heavy periods and endometriosis
Entrepreneur6 days agoKOVE Medical raises €1.7 million to improve safety of foetal surgery
Fertility2 weeks agoOne week left to apply: W Accelerate with Merck KGaA and M Ventures
Pregnancy1 week agoUK study aims to transform maternity care for high-risk pregnancies
Menopause2 weeks agoQuarter of women miss work due to menstual symptoms, survey finds
Mental health2 weeks agoPMDD after SSRIs or hormones: Why the brain may be the missing treatment target
Diagnosis2 weeks agoArk Surgical secures further institutional backing to accelerate US expansion
Hormonal health4 days agoMenopause hormone treatment may ease brain fog, study suggests












